Lung cancer screening

Clinical practice guidelines in oncology

Douglas E. Wood, George A. Eapen, David S. Ettinger, Lifang Hou, David Jackman, Ella Kazerooni, Donald Klippenstein, Rudy P Lackner, Lorriana Leard, Ann N C Leung, Pierre P. Massion, Bryan F. Meyers, Reginald F. Munden, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter & 6 others Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Michael Unger, Stephen C. Yang

Research output: Contribution to journalReview article

160 Citations (Scopus)

Abstract

Lung cancer screening with LDCT is a complex and controversial topic, with inherent risks and benefits. Results from the large, prospective, randomized NLST show that lung cancer screening with LDCT can decrease lung cancer-specific mortality by 20% and even decrease all-cause mortality by 7%,8 The NLST results indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened with LDCT. However, the NLST findings have not been replicated yet in a separate cohort. Further analysis of the NLST is underway, including comparative effectiveness modeling. The cost- effectiveness and true benefit-to-risk ratio for lung cancer screening still must be determined. At some point, an acceptable level of risk will have to be deemed appropriate for the benefits of screening. The NCCN Lung Cancer Screening Panel recommends helical LDCT screening for select patients at high risk for lung cancer based on the NLST results, nonrandomized studies, and observational data. These guidelines discuss in detail the criteria for determining which patients are at high risk, and the algorithm provides recommendations for evaluating and following-up nodules detected on LDCT screening (e.g., solid and part-solid nodules). Smokers should always be encouraged to quit smoking tobacco (http ://www.smokefree .gov/). Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useftil (see Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians; http://www.surgeongeneral .gov/tobacco/tobaqrg.htm). When considering lung cancer screening, it is important to have a full understanding of all risks and benefits related to screening with LDCT. As policies for implementing lung screening programs are designed, a focus on multidisciplinary programs (incorporating primary care doctors, pulmonologists, radiologists, thoracic surgeons, medical oncologists, and pathologists) will be helpful to optimize decision- making and minimize interventions for patients with benign lung disease.

Original languageEnglish (US)
Pages (from-to)240-265
Number of pages26
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Early Detection of Cancer
Practice Guidelines
Lung Neoplasms
Tobacco Use Disorder
Mortality
Tobacco Use
Smoking Cessation
Lung Diseases
Tobacco
Cost-Benefit Analysis
Observational Studies
Counseling
Primary Health Care
Decision Making
Thorax
Smoking
Odds Ratio
Guidelines
Lung

Keywords

  • Carcinogen
  • LDCT smoking
  • Lung cancer
  • NCCN clinical practice guidelines
  • NCCN guidelines
  • Screening
  • Tobacco

ASJC Scopus subject areas

  • Oncology

Cite this

Wood, D. E., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D., Kazerooni, E., ... Yang, S. C. (2012). Lung cancer screening: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 10(2), 240-265. https://doi.org/10.6004/jnccn.2012.0022

Lung cancer screening : Clinical practice guidelines in oncology. / Wood, Douglas E.; Eapen, George A.; Ettinger, David S.; Hou, Lifang; Jackman, David; Kazerooni, Ella; Klippenstein, Donald; Lackner, Rudy P; Leard, Lorriana; Leung, Ann N C; Massion, Pierre P.; Meyers, Bryan F.; Munden, Reginald F.; Otterson, Gregory A.; Peairs, Kimberly; Pipavath, Sudhakar; Pratt-Pozo, Christie; Reddy, Chakravarthy; Reid, Mary E.; Rotter, Arnold J.; Schabath, Matthew B.; Sequist, Lecia V.; Tong, Betty C.; Travis, William D.; Unger, Michael; Yang, Stephen C.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 10, No. 2, 01.02.2012, p. 240-265.

Research output: Contribution to journalReview article

Wood, DE, Eapen, GA, Ettinger, DS, Hou, L, Jackman, D, Kazerooni, E, Klippenstein, D, Lackner, RP, Leard, L, Leung, ANC, Massion, PP, Meyers, BF, Munden, RF, Otterson, GA, Peairs, K, Pipavath, S, Pratt-Pozo, C, Reddy, C, Reid, ME, Rotter, AJ, Schabath, MB, Sequist, LV, Tong, BC, Travis, WD, Unger, M & Yang, SC 2012, 'Lung cancer screening: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 2, pp. 240-265. https://doi.org/10.6004/jnccn.2012.0022
Wood, Douglas E. ; Eapen, George A. ; Ettinger, David S. ; Hou, Lifang ; Jackman, David ; Kazerooni, Ella ; Klippenstein, Donald ; Lackner, Rudy P ; Leard, Lorriana ; Leung, Ann N C ; Massion, Pierre P. ; Meyers, Bryan F. ; Munden, Reginald F. ; Otterson, Gregory A. ; Peairs, Kimberly ; Pipavath, Sudhakar ; Pratt-Pozo, Christie ; Reddy, Chakravarthy ; Reid, Mary E. ; Rotter, Arnold J. ; Schabath, Matthew B. ; Sequist, Lecia V. ; Tong, Betty C. ; Travis, William D. ; Unger, Michael ; Yang, Stephen C. / Lung cancer screening : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2012 ; Vol. 10, No. 2. pp. 240-265.
@article{861ffbe8dece414aaabae1aa2ef26bd1,
title = "Lung cancer screening: Clinical practice guidelines in oncology",
abstract = "Lung cancer screening with LDCT is a complex and controversial topic, with inherent risks and benefits. Results from the large, prospective, randomized NLST show that lung cancer screening with LDCT can decrease lung cancer-specific mortality by 20{\%} and even decrease all-cause mortality by 7{\%},8 The NLST results indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened with LDCT. However, the NLST findings have not been replicated yet in a separate cohort. Further analysis of the NLST is underway, including comparative effectiveness modeling. The cost- effectiveness and true benefit-to-risk ratio for lung cancer screening still must be determined. At some point, an acceptable level of risk will have to be deemed appropriate for the benefits of screening. The NCCN Lung Cancer Screening Panel recommends helical LDCT screening for select patients at high risk for lung cancer based on the NLST results, nonrandomized studies, and observational data. These guidelines discuss in detail the criteria for determining which patients are at high risk, and the algorithm provides recommendations for evaluating and following-up nodules detected on LDCT screening (e.g., solid and part-solid nodules). Smokers should always be encouraged to quit smoking tobacco (http ://www.smokefree .gov/). Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useftil (see Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians; http://www.surgeongeneral .gov/tobacco/tobaqrg.htm). When considering lung cancer screening, it is important to have a full understanding of all risks and benefits related to screening with LDCT. As policies for implementing lung screening programs are designed, a focus on multidisciplinary programs (incorporating primary care doctors, pulmonologists, radiologists, thoracic surgeons, medical oncologists, and pathologists) will be helpful to optimize decision- making and minimize interventions for patients with benign lung disease.",
keywords = "Carcinogen, LDCT smoking, Lung cancer, NCCN clinical practice guidelines, NCCN guidelines, Screening, Tobacco",
author = "Wood, {Douglas E.} and Eapen, {George A.} and Ettinger, {David S.} and Lifang Hou and David Jackman and Ella Kazerooni and Donald Klippenstein and Lackner, {Rudy P} and Lorriana Leard and Leung, {Ann N C} and Massion, {Pierre P.} and Meyers, {Bryan F.} and Munden, {Reginald F.} and Otterson, {Gregory A.} and Kimberly Peairs and Sudhakar Pipavath and Christie Pratt-Pozo and Chakravarthy Reddy and Reid, {Mary E.} and Rotter, {Arnold J.} and Schabath, {Matthew B.} and Sequist, {Lecia V.} and Tong, {Betty C.} and Travis, {William D.} and Michael Unger and Yang, {Stephen C.}",
year = "2012",
month = "2",
day = "1",
doi = "10.6004/jnccn.2012.0022",
language = "English (US)",
volume = "10",
pages = "240--265",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Lung cancer screening

T2 - Clinical practice guidelines in oncology

AU - Wood, Douglas E.

AU - Eapen, George A.

AU - Ettinger, David S.

AU - Hou, Lifang

AU - Jackman, David

AU - Kazerooni, Ella

AU - Klippenstein, Donald

AU - Lackner, Rudy P

AU - Leard, Lorriana

AU - Leung, Ann N C

AU - Massion, Pierre P.

AU - Meyers, Bryan F.

AU - Munden, Reginald F.

AU - Otterson, Gregory A.

AU - Peairs, Kimberly

AU - Pipavath, Sudhakar

AU - Pratt-Pozo, Christie

AU - Reddy, Chakravarthy

AU - Reid, Mary E.

AU - Rotter, Arnold J.

AU - Schabath, Matthew B.

AU - Sequist, Lecia V.

AU - Tong, Betty C.

AU - Travis, William D.

AU - Unger, Michael

AU - Yang, Stephen C.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Lung cancer screening with LDCT is a complex and controversial topic, with inherent risks and benefits. Results from the large, prospective, randomized NLST show that lung cancer screening with LDCT can decrease lung cancer-specific mortality by 20% and even decrease all-cause mortality by 7%,8 The NLST results indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened with LDCT. However, the NLST findings have not been replicated yet in a separate cohort. Further analysis of the NLST is underway, including comparative effectiveness modeling. The cost- effectiveness and true benefit-to-risk ratio for lung cancer screening still must be determined. At some point, an acceptable level of risk will have to be deemed appropriate for the benefits of screening. The NCCN Lung Cancer Screening Panel recommends helical LDCT screening for select patients at high risk for lung cancer based on the NLST results, nonrandomized studies, and observational data. These guidelines discuss in detail the criteria for determining which patients are at high risk, and the algorithm provides recommendations for evaluating and following-up nodules detected on LDCT screening (e.g., solid and part-solid nodules). Smokers should always be encouraged to quit smoking tobacco (http ://www.smokefree .gov/). Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useftil (see Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians; http://www.surgeongeneral .gov/tobacco/tobaqrg.htm). When considering lung cancer screening, it is important to have a full understanding of all risks and benefits related to screening with LDCT. As policies for implementing lung screening programs are designed, a focus on multidisciplinary programs (incorporating primary care doctors, pulmonologists, radiologists, thoracic surgeons, medical oncologists, and pathologists) will be helpful to optimize decision- making and minimize interventions for patients with benign lung disease.

AB - Lung cancer screening with LDCT is a complex and controversial topic, with inherent risks and benefits. Results from the large, prospective, randomized NLST show that lung cancer screening with LDCT can decrease lung cancer-specific mortality by 20% and even decrease all-cause mortality by 7%,8 The NLST results indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened with LDCT. However, the NLST findings have not been replicated yet in a separate cohort. Further analysis of the NLST is underway, including comparative effectiveness modeling. The cost- effectiveness and true benefit-to-risk ratio for lung cancer screening still must be determined. At some point, an acceptable level of risk will have to be deemed appropriate for the benefits of screening. The NCCN Lung Cancer Screening Panel recommends helical LDCT screening for select patients at high risk for lung cancer based on the NLST results, nonrandomized studies, and observational data. These guidelines discuss in detail the criteria for determining which patients are at high risk, and the algorithm provides recommendations for evaluating and following-up nodules detected on LDCT screening (e.g., solid and part-solid nodules). Smokers should always be encouraged to quit smoking tobacco (http ://www.smokefree .gov/). Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useftil (see Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians; http://www.surgeongeneral .gov/tobacco/tobaqrg.htm). When considering lung cancer screening, it is important to have a full understanding of all risks and benefits related to screening with LDCT. As policies for implementing lung screening programs are designed, a focus on multidisciplinary programs (incorporating primary care doctors, pulmonologists, radiologists, thoracic surgeons, medical oncologists, and pathologists) will be helpful to optimize decision- making and minimize interventions for patients with benign lung disease.

KW - Carcinogen

KW - LDCT smoking

KW - Lung cancer

KW - NCCN clinical practice guidelines

KW - NCCN guidelines

KW - Screening

KW - Tobacco

UR - http://www.scopus.com/inward/record.url?scp=84863170471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863170471&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0022

DO - 10.6004/jnccn.2012.0022

M3 - Review article

VL - 10

SP - 240

EP - 265

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 2

ER -